查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984159

細胞和基因治療藥物輸送裝置市場：按產品類型、裝置類型、治療方法、分銷管道和最終用戶分類－2026-2032年全球市場預測

Cell & Gene Therapy Drug Delivery Devices Market by Product Type, Device Type, Therapy Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，用於細胞和基因治療的藥物輸送裝置的市值將達到 33.9 億美元，到 2026 年將成長到 44.8 億美元，到 2032 年將達到 267.9 億美元，複合年成長率為 34.33%。

主要市場統計數據
基準年 2025 33.9億美元
預計年份：2026年 44.8億美元
預測年份 2032 267.9億美元
複合年成長率 (%) 34.33%

前瞻性的介紹概述了影響先進生物製藥輸送裝置策略的技術、臨床和監管挑戰。

先進生物製藥與精準給藥裝置的融合正在重塑臨床醫生和醫療保健系統應對複雜治療方法的方式。裝置工程、材料科學和互聯技術的最新創新為提高細胞和基因療法的給藥準確性、患者依從性和安全性創造了新的機會。同時，涉及活細胞和基因載體的臨床項目對裝置的適用性、低溫運輸物流和無菌給藥提出了嚴格的要求，這需要對產品設計和操作流程進行新的評估。

對正在重新定義藥物輸送的器材技術、分散式醫療和監管融合的關鍵趨勢進行全面分析。

細胞和基因治療輸送裝置的格局正在經歷一場變革，其驅動力來自治療複雜性的提升、以患者為中心的護理模式的興起以及與數位醫療的融合。治療方法研發人員越來越重視微創和門診給藥，促使醫療設備製造商不斷創新，研發出自動化注射器、無針注射器、微流體系統和穿戴式輸注平台等產品，以減少病患對診所的依賴。同時，分散式醫療的趨勢也加速了對便於居家使用的醫療設備的投資，這些器材既能滿足患者對生物製藥的儲存管理和環境控制需求，又能確保其操作便捷。

對 2025 年前的累積關稅措施如何重塑行政管理系統的採購、供應商選擇和製造的韌性進行策略評估。

針對進口醫療組件和成品醫療設備的新關稅措施的訂定，給支持細胞和基因治療輸送系統的供應鏈帶來了巨大壓力。這些將於2025年前逐步實施的累積關稅措施，將推高自動注射器、輸液幫浦和一次性耗材中使用的某些上游原料、特殊聚合物和精密組件的成本。因此，採購團隊正在重新審視其供應商組合，探索替代貨源，並重新評估其總到岸成本模型，以維持專案的可行性和價格透明度。

深入了解將醫療設備類型、最終用戶、產品形式、治療方法和通路與策略性產品決策連結起來的詳細細分市場。

將產品開發和商業化策略與臨床和營運實際情況相結合，需要對細分市場動態有深刻的理解。就設備類型而言，競爭格局涵蓋自動注射器、植入式幫浦、輸液幫浦、微流體裝置、無針注射器、預填充式注射器和傳統注射器，每種裝置在精確給藥、便攜性和監管複雜性之間都存在獨特的權衡取捨。同樣，終端用戶分析也凸顯了診所、居家醫療機構、醫院和專科醫療中心的不同需求。醫院需要整合的設備生態系統和高通量可靠性，而居家醫療和專科醫療中心則優先考慮易用性、緊湊的外形尺寸和遠端監控功能。

本研究務實地檢驗了區域法規環境、基礎設施成熟度和醫療保健服務模式如何影響設備的部署和採用。

區域趨勢對醫療器材策略、監管互動和商業化實施有顯著影響，因此需要針對不同區域採取差異化的有效規劃方法。在美洲，臨床試驗活動、集中化的高品質醫療中心以及完善的醫保報銷體系促進了新型給藥方案的快速普及；然而，明確的醫保報銷路徑和與支付方的積極互動對於更廣泛的應用仍然至關重要。歐洲、中東和非洲（EMEA）的監管環境複雜多樣，各國醫療設備框架和採購模式各不相同，因此需要製定針對特定情況的監管策略和區域價值提案。該地區某些司法管轄區也透過集中採購和與公共醫療體系的整合提供了巨大的發展機會。亞太地區是快速創新、醫院基礎設施不斷完善以及日益重視分散式醫療模式的中心，但相關人員必須應對特定市場的監管時間表和物流挑戰。

本報告深入分析了製造商、創新者和服務供應商如何協調其業務運營和夥伴關係，以加速採用基於醫療設備的治療方法。

在輸液裝置領域，影響競爭優勢的許多策略挑戰正匯聚成企業行為的關鍵模式。成熟的醫療技術公司正利用其豐富的監管經驗、生產規模和分銷網路，拓展至專業輸液系統領域，並經常尋求與治療方法開發商建立合作關係或達成許可協議，以開發整合複合產品。同時，敏捷的Start-Ups和裝置開發人員則透過模組化輸液架構、緊湊型微流體處理器和配備感測器的自動注射器等平台技術進行差異化。這些技術旨在解決特定的臨床難題，並能快速提升人體工學和連結性。

為醫療器材開發公司和治療方法贊助商提供一套可操作且優先排序的策略建議，以協調創新、供應彈性和監管合規性。

行業領導者應採取整合式方法，將醫療設備創新與臨床工作流程、監管策略和商業性執行相結合，以最大限度地發揮先進生物製藥的治療和營運價值。首先，應在設計過程早期就納入人體工學和臨床醫生參與，以確保醫療設備滿足實際應用環境（無論是在醫院、專科醫療中心、診所或家庭環境中）的實際限制。這種早期整合可以減少返工並加快監管核准。其次，對於關鍵零件，應建立多元化的供應鏈，納入合格的二級供應商和近岸外包選項，以降低關稅和前置作業時間風險，同時保持嚴格的品質管治。

我們高度透明的混合方法研究途徑，將與專家的直接訪談與第二手資料的整合相結合，確保了嚴謹而實用的見解。

本研究採用混合方法，將質性專家見解與嚴謹的二次檢驗結合，以產生可操作的見解。主要資訊來源包括對醫療設備工程師、臨床研究人員、藥局主任和供應鏈高階主管的詳細訪談，以及與監管專家的結構化諮詢，以了解申報和上市後要求。透過與相關人員的對話，旨在捕捉有關醫療設備易用性、病毒和非病毒載體的防護要求以及醫院、診所、專科醫療中心和居家照護機構的實際限制等方面的經驗性細微差別。

簡明結論總結道，醫療設備創新、營運韌性和相關人員之間的協作是決定治療實施成功與否的關鍵因素。

整體結論顯而易見：細胞和基因療法的成功應用不僅需要生物製劑本身，還需要給藥系統的設計和物流協調。設備技術的創新，結合數位化連接和自適應分銷模式，使得複雜治療方法的去中心化程度更高，同時也提高了對人為因素、低溫運輸管理以及與監管機構協調的要求。同時，關稅政策的變化和區域基礎設施差異等外部因素，使得積極主動的供應鏈策略和立足本地的商業化方法至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：細胞與基因治療藥物輸送裝置市場：依產品類型分類

  • 可重複使用的
  • 一次性的

第9章：細胞與基因治療藥物輸送裝置市場：依裝置類型分類

  • 自動噴油器
  • 嵌入式泵浦
  • 點滴幫浦
  • 微流體裝置
  • 無針注射器
  • 預填充式注射器
  • 注射器

第10章：細胞與基因治療藥物輸送裝置市場－依治療方法分類

  • 細胞療法
    • CAR-T療法
    • 樹突細胞療法
    • 幹細胞療法
  • 基因治療
    • 非病毒載體
    • 病毒載體

第11章：細胞與基因治療藥物輸送裝置市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
    • 郵購藥房
    • 傳統網路藥局
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章：細胞與基因治療藥物輸送裝置市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院
  • 專業醫療中心

第13章：細胞與基因治療藥物傳遞裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：細胞與基因治療藥物輸送裝置市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：細胞與基因治療藥物輸送裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國細胞與基因治療藥物傳遞裝置市場

第17章：中國細胞與基因治療藥物輸送裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • B. Braun Melsungen AG
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • Catalent, Inc.
  • Dendreon Pharmaceuticals LLC.
  • Fresenius SE & Co. KGaA
  • Gerresheimer AG
  • Helixmith Co., Ltd.
  • ICU Medical, Inc.
  • Kite Pharma, Inc. by Gilead
  • Kolon TissueGene, Inc.
  • MaxCyte, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • Terumo Corporation
  • uniQure NV
  • Vericel Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 3.39 billion in 2025 and is projected to grow to USD 4.48 billion in 2026, with a CAGR of 34.33%, reaching USD 26.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.39 billion
Estimated Year [2026] USD 4.48 billion
Forecast Year [2032] USD 26.79 billion
CAGR (%) 34.33%

A forward-looking introduction that frames the technical, clinical, and regulatory imperatives shaping delivery device strategies for advanced biologics

The convergence of advanced biologics and precision delivery devices is reshaping how clinicians and healthcare systems approach complex therapies. Recent innovations in device engineering, materials science, and connectivity have created new opportunities to improve dosing accuracy, patient adherence, and safety for cell and gene therapies. At the same time, clinical program requirements for handling living cells and genetic vectors impose exacting constraints on device compatibility, cold chain logistics, and aseptic administration, demanding a fresh evaluation of product design and operational workflows.

Stakeholders across product development, clinical operations, and commercial strategy now face a bifurcated challenge: integrate enabling delivery technologies that preserve therapeutic integrity while minimizing complexity for end users, and simultaneously navigate increasingly stringent regulatory expectations for combination product evaluation. These dynamics have elevated cross-disciplinary collaboration as a critical success factor, with engineers, translational scientists, and regulatory experts needing to converge earlier in development cycles. As a result, organizations that prioritize integrated device-therapy development, robust human factors engineering, and clear regulatory engagement pathways are better positioned to advance clinical adoption and scale treatment delivery.

A comprehensive exploration of the major transformative trends in device technology, decentralized care, and regulatory convergence redefining therapeutic delivery

The landscape for cell and gene therapy delivery devices is undergoing transformative shifts driven by parallel advances in therapy complexity, patient-centric care models, and digital health integration. Therapy developers increasingly prioritize minimally invasive delivery and outpatient administration, prompting device makers to innovate with autoinjectors, needle-free injectors, microfluidic systems, and wearable infusion platforms that reduce clinic dependency. At the same time, the trend toward decentralized care has accelerated investment in devices that are intuitive for home use while maintaining chain-of-custody and environmental controls for sensitive biologics.

Concurrently, manufacturing and supply chain sophistication are rising to meet the demands of personalized and batch-limited therapies. Microfluidic devices and modular infusion systems are being explored to enable localized processing and point-of-care manipulation of cell products, which could shorten critical timelines between harvest, manipulation, and delivery. Regulatory authorities are adapting guidance to address combination products and the intersection of device and biologic review, which is prompting more proactive engagement between sponsors and regulators. Moreover, digital connectivity and remote monitoring capabilities are being embedded into devices to provide real-time adherence and safety data, supporting iterative improvements in therapy protocols and post-market surveillance. Taken together, these shifts create both opportunities and complexities, and organizations must adopt integrated development pathways and robust stakeholder collaboration to capitalize on the evolving environment.

A strategic assessment of how cumulative tariff measures through 2025 are reshaping procurement, sourcing, and manufacturing resilience for delivery systems

The introduction of new tariff measures affecting imported medical components and finished devices is exerting measurable pressure on the supply chains that underpin cell and gene therapy delivery systems. Cumulative tariff actions enacted through 2025 have increased costs for certain upstream raw materials, specialized polymers, and precision components used in autoinjectors, infusion pumps, and single-use disposables. As a consequence, procurement teams are recalibrating supplier portfolios, exploring alternative sources, and reassessing total landed cost models to maintain program viability and pricing transparency.

In response, many manufacturers have initiated dual strategies of supplier diversification and nearshoring where feasible, seeking to minimize exposure to tariff volatility and reduce lead times for critical components. These approaches lead to trade-offs: relocating production can reduce tariff risk but may require capital investment, workforce training, and new quality system validations. Additionally, tariff-driven cost increases have implications for contract manufacturing negotiations and long-term supply agreements, elevating the importance of clear commercial terms, risk-sharing structures, and contingency planning.

Regulatory compliance and traceability requirements further complicate mitigation efforts, as sourcing alterations necessitate revalidation and potential device submission updates. Therefore, organizations must adopt scenario-based procurement planning that integrates tariff sensitivity, supplier qualification timelines, and regulatory impact assessments to preserve continuity of supply and maintain treatment accessibility.

A detailed set of segmentation insights linking device types, end users, product formats, therapy modalities, and distribution pathways to strategic product decisions

A nuanced understanding of segmentation dynamics is essential for aligning product development and commercialization strategies with clinical and operational realities. When studied by device type, the competitive landscape spans autoinjectors, implantable pumps, infusion pumps, microfluidic devices, needle-free injectors, pre-filled syringes, and conventional syringes, each offering distinct trade-offs between precision dosing, portability, and regulatory complexity. Likewise, analysis by end user highlights divergent needs across clinics, homecare settings, hospitals, and specialty centers; hospitals demand integrated device ecosystems and high-throughput reliability, while homecare and specialty centers prioritize ease of use, compact form factors, and remote monitoring capabilities.

Product type segmentation emphasizes the contrast between reusable systems that support lifecycle servicing and single-use disposables that simplify sterility and reduce cross-contamination risk, informing choices around maintenance infrastructure and unit economics. Therapy type segmentation divides the space into cell therapy and gene therapy; within cell therapy, CAR-T therapies, dendritic cell approaches, and stem cell treatments each impose unique handling, administration route, and timing constraints, whereas gene therapy pathways differentiate non-viral vector and viral vector strategies with implications for containment, dosing accuracy, and regulatory dossier composition. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy, with online pharmacy further split into mail order and traditional online models and retail pharmacy further differentiated between chain and independent outlets, underscore how logistics, cold chain requirements, and point-of-care coordination vary by pathway. Integrating these segmentation perspectives enables targeted product roadmaps and distribution strategies that reflect real-world use cases and stakeholder preferences.

A pragmatic examination of how regional regulatory environments, infrastructure maturity, and healthcare delivery models influence device deployment and adoption

Regional dynamics exert a profound influence on device strategy, regulatory engagement, and commercialization execution, and effective planning requires a regionally differentiated approach. In the Americas, clinical trial activity, concentrated centers of excellence, and a progressive reimbursement environment support rapid adoption of novel delivery solutions, while reimbursement pathway clarity and payer engagement remain critical for broader uptake. Europe, the Middle East & Africa present a heterogeneous regulatory landscape, where varying national device frameworks and divergent procurement models necessitate adaptive regulatory strategies and localized value propositions; this region also offers strong opportunities for centralized procurement and collaborations with public health systems in certain jurisdictions. Asia-Pacific combines rapid innovation hubs, expanding hospital infrastructure, and an increasing focus on decentralized care models, but stakeholders must navigate diverse regulatory timelines and logistics challenges across markets.

Across regions, cold chain infrastructure maturity, healthcare workforce capacity, and patient access models shape the practical viability of complex biologic administrations outside specialized centers. Therefore, companies must prioritize region-specific evidence generation, tailored training programs for clinicians and caregivers, and distribution partnerships that align with local pharmacy and hospital procurement practices. Coordinated regional strategies that balance global standards with local adaptability will be essential to scale advanced therapies while ensuring consistent quality and patient safety.

An incisive look at how manufacturers, innovators, and service providers are aligning operations and partnerships to accelerate device-enabled therapy adoption

Key corporate behaviors are converging around several strategic imperatives that influence competitive positioning in the delivery device segment. Established medtech firms are leveraging deep regulatory experience, manufacturing scale, and distribution networks to expand into specialty delivery systems, frequently pursuing partnerships or licensing arrangements with therapy developers to create integrated combination products. At the same time, agile startups and device innovators are differentiating through platform technologies-such as modular infusion architectures, compact microfluidic processors, and sensor-enabled autoinjectors-that address specific clinical pain points and enable faster iteration of human factors and connectivity features.

Contract development and manufacturing organizations play an increasingly central role, offering clean-room capacity, scalable assembly, and sterilization services that are essential for single-use disposables and complex combination products. Meanwhile, companies specializing in cold chain logistics and validated transport systems are becoming strategic partners for therapy sponsors seeking predictable delivery windows and traceability for temperature-sensitive biologics. Across the ecosystem, successful players adopt collaborative go-to-market strategies, invest in early regulatory dialogue, and prioritize rigorous human factors studies to de-risk adoption. Competitive differentiation increasingly hinges on the ability to demonstrate real-world reliability, interoperability with clinical workflows, and post-market data collection capabilities that support ongoing safety and performance monitoring.

A practical and prioritized set of strategic recommendations for device developers and therapy sponsors to align innovation, supply resilience, and regulatory readiness

Industry leaders should pursue an integrated approach that aligns device innovation with clinical workflow, regulatory strategy, and commercial execution to capture the full therapeutic and operational value of advanced biologics. First, embed human factors and clinician engagement early in the design process to ensure devices meet practical constraints of administration environments, whether in a hospital, specialty center, clinic, or the home. This early alignment reduces rework and accelerates regulatory acceptance. Second, cultivate diversified supply chains with qualified secondary suppliers and nearshoring options for critical components to mitigate tariff exposure and lead-time risk while maintaining robust quality governance.

Third, establish cross-functional teams that include regulatory, translational, manufacturing, and commercial stakeholders to navigate combination product pathways and to plan for post-market surveillance and real-world evidence collection. Fourth, invest in digital enablement-connectivity, remote monitoring, and analytics-to enhance adherence, detect early safety signals, and provide evidence of value to payers and providers. Finally, develop flexible distribution strategies that reflect differences across hospital pharmacies, online and mail order models, chain and independent retail networks, and outpatient care settings. By implementing these actions, organizations can reduce commercialization friction, support patient-centric care models, and build resilient operations that accommodate evolving therapy paradigms.

A transparent mixed-methods research approach combining primary expert engagements and secondary evidence synthesis to ensure rigorous and actionable insights

This research employs a mixed-methods approach that synthesizes qualitative expert insight with rigorous secondary validation to produce actionable findings. Primary inputs include in-depth interviews with device engineers, clinical investigators, pharmacy directors, and supply chain executives, combined with structured consultations with regulatory specialists to understand submission and post-market requirements. These stakeholder engagements are designed to capture experiential nuances around device usability, containment needs for viral and non-viral vectors, and real-world workflow constraints across hospitals, clinics, specialty centers, and homecare environments.

Secondary analysis draws on publicly available regulatory guidance, peer-reviewed literature, clinical trial registries, and supplier technical datasheets to ground findings in verifiable evidence. The research also integrates case study reviews of representative device-therapy pairings to illustrate design choices, human factors iterations, and logistics solutions. Data triangulation ensures conclusions are corroborated across multiple sources, and methodological transparency is maintained through documented assumptions, interview guides, and validation checkpoints. Throughout, the approach emphasizes reproducibility and stakeholder validation to ensure that insights reflect operational realities and inform practical decision-making across development, regulatory, and commercial functions.

A concise conclusion synthesizing how device innovation, operational resilience, and stakeholder collaboration determine successful therapy delivery outcomes

The cumulative narrative is clear: successful deployment of cell and gene therapies depends as much on delivery system design and logistical orchestration as it does on the biological modality itself. Innovations in device technology, coupled with digital connectivity and adaptive distribution models, are enabling broader decentralization of complex therapies while elevating requirements for human factors, cold chain management, and regulatory coordination. At the same time, external forces such as tariff policy shifts and regional infrastructure disparities necessitate proactive supply chain strategies and localized commercialization approaches.

Organizations that integrate cross-functional teams early, prioritize iterative user-centered design, and engage regulators proactively will reduce technical and commercial risk. Moreover, the effective pairing of device and therapy demands collaboration across a growing ecosystem of manufacturers, contract partners, logistics specialists, and healthcare providers. Ultimately, the path to scalable, safe, and patient-centric delivery of advanced biologics will be determined by the ability of stakeholders to harmonize engineering excellence, operational resilience, and evidence generation throughout the product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Drug Delivery Devices Market, by Product Type

  • 8.1. Reusable
  • 8.2. Single Use

9. Cell & Gene Therapy Drug Delivery Devices Market, by Device Type

  • 9.1. Autoinjector
  • 9.2. Implantable Pump
  • 9.3. Infusion Pump
  • 9.4. Microfluidic Device
  • 9.5. Needle-Free Injector
  • 9.6. Pre-Filled Syringe
  • 9.7. Syringe

10. Cell & Gene Therapy Drug Delivery Devices Market, by Therapy Type

  • 10.1. Cell Therapy
    • 10.1.1. CAR-T Therapy
    • 10.1.2. Dendritic Cell Therapy
    • 10.1.3. Stem Cell Therapy
  • 10.2. Gene Therapy
    • 10.2.1. Non-Viral Vector
    • 10.2.2. Viral Vector

11. Cell & Gene Therapy Drug Delivery Devices Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
    • 11.2.1. Mail Order Pharmacy
    • 11.2.2. Traditional Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Cell & Gene Therapy Drug Delivery Devices Market, by End User

  • 12.1. Clinic
  • 12.2. Homecare
  • 12.3. Hospital
  • 12.4. Specialty Center

13. Cell & Gene Therapy Drug Delivery Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Drug Delivery Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Drug Delivery Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Drug Delivery Devices Market

17. China Cell & Gene Therapy Drug Delivery Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. B. Braun Melsungen AG
  • 18.7. Bausch & Lomb Incorporated
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bluebird bio, Inc.
  • 18.10. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • 18.11. Catalent, Inc.
  • 18.12. Dendreon Pharmaceuticals LLC.
  • 18.13. Fresenius SE & Co. KGaA
  • 18.14. Gerresheimer AG
  • 18.15. Helixmith Co., Ltd.
  • 18.16. ICU Medical, Inc.
  • 18.17. Kite Pharma, Inc. by Gilead
  • 18.18. Kolon TissueGene, Inc.
  • 18.19. MaxCyte, Inc.
  • 18.20. Novartis AG
  • 18.21. Orchard Therapeutics
  • 18.22. Pfizer, Inc.
  • 18.23. Renova Therapeutics
  • 18.24. Spark Therapeutics, Inc.
  • 18.25. Terumo Corporation
  • 18.26. uniQure N.V.
  • 18.27. Vericel Corporation
  • 18.28. West Pharmaceutical Services, Inc.
  • 18.29. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY IMPLANTABLE PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MICROFLUIDIC DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY MAIL ORDER PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY TRADITIONAL ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)